Oncology
5,176 studies502 in 7 days2,477 in 30 days
Filters
Latest
5,176 studies
- “Pseudolymphomatous” angiosarcoma mimicking rhinophyma — case report and focused review of the literature
- Grade 3 cholestatic immune-related hepatitis under cemiplimab for high-risk locally advanced cutaneous squamous cell carcinoma: a case report from Germany
- Meditation Breathing Training and Short-Term Recovery in Patients Undergoing Thoracoscopic Lung Cancer Resection: A Non-Randomized Historical-Control Study.
- Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression
- CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome
- Adult cancer survivors’ mental health needs and experiences in primary care: a scoping review
- Expression of nestin in cancer: a tissue microarray study involving 13,318 cancers from 148 tumor entities.
- XIAP induces inflammation and promotes colorectal cancer progression.
- A testable framework integrates platelet engineering and injectable hydrogels with CAR T cells for localized treatment of microscopic residual disease after breast cancer surgery.
- Pseudotime‐Derived Seven‐Gene Prognostic Signature and TYRP1 in Melanoma
- Adaptation of breast cancer cells to serum-free defined medium reveals changes in proliferation, adhesion, and lipid metabolism
- Synthetic lethality of p97 inhibition and PSMC2-overexpressionovercomes bortezomib resistance in multiple myeloma
- PERTURBATION OF THE AMINO ACID STRESS RESPONSE PATHWAY EXPOSES A METABOLIC VULNERABILITY IN MULTIPLE AGGRESSIVE CANCER SUBTYPES
- Peripheral Axons Form Endoplasmic Reticulum-Rich Conduits With Breast Cancer Cells
- KaryoTap-based scDNA seq assessment of aneuploidy induction by hydroquinone in hematopoietic stem cells
- AMD1-driven MTA production sustains chemoresistance by rewiring PMN-MDSC immunosuppression
- Analytical Validation and Clinical Implementation of MedGenome HRD Assay: A Large Comparative Study Against Commercial HRD Assays in Ovarian Cancer
- Comprehensive real-world utilization, treatment trajectories, and outcomes of immune checkpoint inhibitors across cancer types: the multicenter FAIR-ICI cohort
- Neoadjuvant PD-L1/TGF-β blockade can rapidly disrupt the tumor stroma in head and neck cancer patients.
- B cells and the therapeutic index of checkpoint blockade.
- Nuclear cGAS governs transcription to control lipid metabolism, tumor growth, and therapy response.
- Targeting N-acetyltransferase 10 reprograms Treg function to enhance anti-PD-1 immunotherapy sensitivity in murine lung tumors.
- Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS).
- The genomic afterlife of cancer therapy.
- TARBP2 facilitates renal cell carcinoma immune escape by suppressing 53BP1 phase separation to upregulate B7-H3.